Date: July 27, 2026 2026

Guest Skeptic: Dr. Howard (Howie) Mel is an emergency physician and FACEP. 

Reference: Smith JE et al. SWiFT Trial Group. Prehospital Whole Blood in Traumatic Hemorrhage – a Randomized Controlled Trial. NEJM 2026 March

Case: A 36-year-old man is brought to the emergency department (ED) by air ambulance after a high-speed motorcycle crash. Paramedics report blunt polytrauma, transient hypotension, tachycardia, pelvic instability, and concern for intra-abdominal bleeding. IV/IO access was obtained in the field, and prehospital blood was started. On arrival, he is pale, cool, and diaphoretic, with blood pressure (BP) 86/52 mm Hg, heart rate (HR) 128 bpm, Glasgow Coma Scale (GCS) score of 13, a pelvic binder in place, abdominal distension, and a positive FAST.

Background: Traumatic hemorrhage is one of the classic time-critical problems in emergency care. Patients do not die because their hemoglobin is low on tomorrow’s CBC; they die because they are bleeding now. This is one of the reasons the 11th edition of ATLS has formally prioritized external bleeding before airway management (SGEM Xtra). The new mnemonic is xABCDE, with the “x” standing for exsanguinating hemorrhage. This reinforces early tourniquet use, direct pressure, and hemostatic adjuncts as first-line priorities when appropriate.

For in-hospital-based trauma resuscitation, the PROPPR trial helped move the conversation toward balanced component therapy. In that 2015 RCT, they compared 1:1:1 plasma:platelets:red cells with 1:1:2. The authors showed better secondary outcomes (hemostasis and fewer deaths from exsanguination at 24 hours), even though the primary outcome (overall mortality) was not statistically different (SGEM#109).

The harder question is what should happen before the patient ever reaches the trauma bay. Prehospital transfusion sounds attractive because it shortens the time to blood-based resuscitation, but the evidence has been mixed.

The PAMPer study found lower 30-day mortality with prehospital plasma in patients at risk for hemorrhagic shock transported by air, while RePHILL did not show superiority for a prehospital blood-product strategy over saline (SGEM#369). A pooled post hoc analysis of PAMPer and COMBAT suggested that any benefit from prehospital plasma may be most apparent when transport times are longer, and resuscitation is started early enough to matter. 

For emergency clinicians, the real debate is not whether bleeding trauma patients need blood. They do. The more useful question is which product, for which patient, in which system, and over what transport interval. That is why prehospital transfusion research keeps circling back to logistics, case selection, transport time, and whether a prehospital strategy complements what happens after ED arrival rather than simply adding complexity.

Clinical Question: In trauma patients with life-threatening hemorrhage treated by participating air ambulance services, does prehospital transfusion with up to 2 units of leukocyte-depleted whole blood, compared with standard component therapy (up to 2 units of red cells and 2 units of plasma), reduce the composite of death or massive transfusion within 24 hours?

Reference: Smith JE et al. SWiFT Trial Group. Prehospital Whole Blood in Traumatic Hemorrhage – a Randomized Controlled Trial. NEJM 2026 March

  • Population: Patients of any age with traumatic injury, attended by a participating air ambulance service clinical team, who required prehospital blood transfusion for major traumatic hemorrhage. 
    • Exclusions: Patients were excluded if IV or IO access could not be established, if there was a known objection to blood transfusion, or if blood products had already been given before the participating air ambulance service arrived. For the main modified intention-to-treat analysis, nontraumatic hemorrhage and traumatic cardiac arrest on arrival of the air ambulance were excluded. 
  • Intervention: Up to 2 units of prehospital leukocyte-depleted whole blood. 
  • Comparison: Up to 2 units of red blood cells and 2 units of plasma (thawed fresh frozen plasma or lyophilized plasma, depending on service). 
  • Outcomes:
    • Primary Outcome: Composite of death from any cause or massive transfusion within 24 hours after randomization. Massive transfusion was defined as at least 10 units of blood components/products in adults, and at least 40 mL/kg in pediatric participants under 16 years weighing under 50 kg. 
    • Secondary outcomes: All-cause mortality at 6 hours, 24 hours, 30 days, and 90 days; massive transfusion; organ-failure–free days up to 30 days; days in critical care and acute care hospital; units of blood products received in 24 hours; cell salvage; additional hemostatic agents; coagulopathy; acid-base disturbance; thrombotic events; transfusion reactions/events; and planned cost-effectiveness and quality-of-life analyses. 
  • Type of Study: Pragmatic, multicenter, parallel-group, open-label (unblinded), superiority randomized controlled trial (RCT).

Authors’ Conclusions: “Among participants with life-threatening hemorrhage, prehospital transfusion of 2 units of whole blood was not superior to standard care in reducing the risk of death or massive transfusion within 24 hours.”

Quality Checklist for Randomized Clinical Trials:

  1. Did the study population include or focus on those in the emergency department? No
  2. Were the patients adequately randomized? Yes
  3. Was the randomization process concealed? Yes
  4. Were the patients analyzed in the groups to which they were randomized (i.e. intention-to-treat analysis)? No
  5. Were the patients recruited consecutively (i.e. no selection bias)? Unsure
  6. Were both groups similar with respect to prognostic factors? Yes
  7. Were all participants (patients, clinicians, outcome assessors) unaware of group allocation (blinded/masked)? No
  8. Were all groups treated equally except for the intervention? Unsure
  9. Was the follow-up complete (i.e. at least 80% for both groups)? Yes
  10. Were all patient-important outcomes considered? Unsure
  11. Was the treatment effect large enough and precise enough to be clinically significant? No
  12. Who funded the trial? NHS Blood and Transplant, participating Air Ambulance Charities, and the Ministry of Defence. The sponsor was NHS Blood and Transplant. 
  13. Did the authors declare any conflicts of interest? Unsure from the main paper files alone, but the protocol states that at the time it was written, the chief investigators, principal investigators, and trial committees had no competing interests, with a plan for disclosure of any arising conflicts during the trial.

Results: A total of 942 patients were randomized overall. After exclusions and data removal, 641 participants comprised the modified intention-to-treat population (327 whole blood, 314 standard care). The primary outcome analysis used complete cases: 314 in the whole-blood group and 302 in the standard-care group. Most participants were male (76%), the majority had blunt trauma (71%), and the median age was 38 years in the whole-blood group and 35 years in the standard-care group. 

Key Result: Prehospital transfusion with up to 2 units of whole blood was not superior to standard component therapy for reducing 24-hour death or massive transfusion in patients with life-threatening traumatic hemorrhage.

  • Primary Outcome: Occurred in 153/314 (48.7%) in the whole-blood group and 144/302 (47.7%) in the standard-care group, for a relative risk of 1.02 (95% CI 0.80 to 1.31; P=0.84). 
  • Secondary Outcomes: Mortality at 6 hours, 24 hours, 30 days, and 90 days appeared similar between groups, as did the rate of massive transfusion and most other secondary outcomes. One notable difference was that prothrombin time above the normal range was more common in the whole-blood group (40.7% vs 30.5%; RR 1.31, 95% CI 1.10 to 1.56). Serious adverse events were slightly fewer with whole blood (31 vs 37), thrombotic events appeared similar, and two transfusion-related/SHOT-type events occurred in standard care with none reported in whole blood.

1. Modified ITT Analysis (mITT): In SWiFT, the main analysis was modified intention-to-treat, excluding nontraumatic hemorrhage, traumatic cardiac arrest on arrival, and patients whose data were withdrawn or deleted after a serious protocol breach. On top of that, the primary analysis was effectively a complete-case analysis within the modified ITT population. Some of these exclusions were clinically reasonable, but they still weaken the integrity of randomization and raise the possibility that excluded participants differed in important ways from included participants. 

Open Label

2. Open label: This was an unmasked trial once the box was opened. Death is a hard outcome, but “massive transfusion” is not purely biological; it is somewhat subjective and depends partly on clinician decisions, local transfusion behaviour, and downstream management. That makes the composite more vulnerable to performance bias than a purely objective endpoint, such as mortality alone. 

3. Contamination & Protocol Slippage: A clean superiority trial needs meaningful separation between groups. In SWiFT, protocol deviations occurred in roughly 7% of both groups, randomization errors occurred in about 5%, and 7 participants in the standard-care arm received whole blood prehospital due to mispacked boxes or because only whole-blood boxes were available. There was also co-enrollment in other studies, including some deemed non-permissible. None of this invalidates the study outright, but it can dilute differences between groups and make a truly superior intervention harder to detect. 

4. Lack of Power: The trial was powered for the primary composite, not for most secondary outcomes. Meanwhile, missingness was modest for the primary outcome but substantial for some secondary and safety measures: 90-day vital status was missing in roughly 13%, thrombosis data in about 19%, and trauma-registry severity variables in about 31%. Incomplete follow-up and selective availability of outcome data weaken confidence in estimates, especially for secondary and safety analyses and should raise our skepticism. So, while the thrombosis and serious adverse event findings are reassuring, they are far from definitive.

5. External Validity: SWiFT was a pragmatic trial, and that is a strength. However, the decision to open a trial box depended on the clinician’s judgment that the patient required prehospital transfusion. That makes the enrolled population highly relevant to UK air-ambulance practice. It also makes it harder to know how reproducible the entry decision would be across clinicians, services, or countries. In other words, the study tells us a lot about a mature physician-paramedic air-ambulance system in England, but less about ground EMS systems, different blood-supply models, or shorter-transport environments and different countries. That is more of an external-validity concern than an internal one, but it still matters when deciding how far to generalize the findings.

Comment on the Authors’ Conclusion Compared to the SGEM Conclusion: We generally agree with the authors’ conclusions, with the friendly amendment to say “whole blood was not superior to standard component care”...

SGEM Bottom Line: Whole blood was feasible and reasonably safe in a UK air-ambulance system, but this trial did not show superiority over standard component therapy.

Case Resolution: The patient is in hemorrhagic shock from major blunt trauma. The priority is not to debate blood-product philosophy at the bedside. The priority is to:

  • Activate the trauma and major hemorrhage pathways.
  • Continue rapid blood-based resuscitation with the product your system can deliver immediately and reliably.
  • Control hemorrhage fast: pelvic stabilization, damage-control surgery and/or intraventional radiology, plus adjuncts like TXA where appropriate.
  • Avoid assuming that whole blood is clearly superior to balanced component therapy, as this trial did not show superiority.

Dr. Howie Mel

Clinical Application: Whole blood is a reasonable option in systems that can store, deliver, and safely govern it. Standard balanced component therapy remains a reasonable standard. Decisions should be driven by logistics, transport interval, wastage, donor availability, training, and how well the prehospital strategy integrates with trauma-bay care, not by the assumption that whole blood is automatically superior.

What Do I Tell the Patient? The most important thing right now is to treat severe bleeding quickly, control the bleeding source, and provide blood products.

Keener Kontest: Last week’s winner was Dr. Tim Kolosionek, a Medical toxicology fellow at Lehigh Valley, Jefferson Health, Allentown, PA. He knew severe sepsis the retired sepsis term.

Listen to the SGEM podcast for this week’s question. If you know the answer, then send an email to thesgem@gmail.com with “keener” in the subject line. The first correct answer will receive a shout-out.

Other FOAMed:

Remember to be skeptical of anything you learn, even if you heard it on the Skeptics’ Guide to Emergency Medicine.